

Fotios LOUPAKIS, MD PhD - CURRICULUM VITAE SHORT VERSION



PERSONAL DATA

Date of birth: January 25th, 1979

Place of birth: Pisa, Italy

Citizenship: Italian

Home address:

Strada Gesù Nazzeno, 28

01100 Viterbo, ITALY

E-mail: fotiosloupakis@gmail.com

CURRENT POSITIONS

CEO and CO-founder 3trees srl – *Innovative Start-Up - Nutraceuticals*

Scientific Director Medendi – *Oncology Genomic Profiling and Consulting Company*

EDUCATION and POST-GRADUATE TRAINING

<i>M.D. Degree (M.D.)</i>	University of Pisa, Italy	Oct 8th 2003
<i>Master of Science in Clinical Trials (M.S.)</i>	University of Pisa, Italy	Dec 31st 2005
<i>Specialty in Oncology</i>	Department of Oncology University of Pisa, Italy	Oct 30th 2007
<i>Research Doctorate in Health Biotechnologies (Ph.D.)</i>	Department of Oncology University of Pisa, Italy	Jun 15th 2011

POSITIONS HELD

<i>Fellow</i>	General Hospital of Livorno Azienda USL6 Livorno, Italy	Oct 2003 – Oct 2007
<i>Medical Oncologist</i>	General Hospital of Livorno Azienda USL6 Livorno, Italy	Nov 2008 – Feb 2009
<i>Medical Oncologist</i>	University Hospital Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy	Feb 2009 – Jun 2016
<i>Assistant Professor</i>	Department of Oncology University of Pisa, Italy	Jan 2010 – Jun 2016
<i>Research Fellow</i>	University of Southern California Keck School of Medicine, Los Angeles, CA – United States	Jul 2011 – Feb 2012

<i>Coordinator Colorectal Cancer Multidisciplinary Team</i>	University Hospital Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy	May 2012 – Jun 2016
<i>Coordinator Clinical Trials Office</i>	University Hospital Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy	Jun 2012 – Jun 2016
<i>Medical Oncologist</i>	Istituto Oncologico Veneto, IRCCS Padua, Italy	Jun 2016 – Mar 2021
<i>Coordinator Translational Research in Gastrointestinal Cancers Team</i>	Istituto Oncologico Veneto, IRCCS Padua, Italy	Jan 2019 – Mar 2021
<i>Therapeutic Area Lead GU/GI Medical Affairs AstraZeneca</i>	AstraZeneca Spa Milan, Italy	May 2021 – May 2023
<i>EMEA Solid Tumors Director Medical Affairs</i>	Menarini Stemline	May 2023 – Dec 2023
<i>CEO and Co-founder</i>	3trees Healthcare	Feb 2023 - present

Pharma Industry Career at AZ

- As Therapeutic Area Lead Medical Affairs – AZ Italy creation of the Gastrointestinal Tumors team (hiring: 1 Sr Medical Advisor, 1 MSL Manager, 3 MSLs). Guidance of the team through Data Read Outs of 2 Major Registrative Phase 3 trials until recent EMA Approval. Launch Readiness and cross functional work with Market Access and Strategy Team for Building the new Gastrointestinal Tumors Franchise (Including Marketing and Field Force).
- Creation of the Genitourinary Team (hiring: 1 Sr Medical Advisor, 1 MSL Manager, 3 MSLs). Guidance of the team through Data Read Outs of 1 Major Registrative Phase 3 trial until recent EMA Approval. Launch Readiness and cross functional work with Market Access and Marketing Team.
- Lead of the Gynaecologic Cancers Team (since April 2022).
- Participation to Regional and Global Medical Teams (focus on Liver Cancers and Prostate Cancer indications).
- Completion of Global Career Development Programs (AZ Rising Leaders Program).
- Regular and Intense cross-functional work with Market Access (including Reimbursement Discussion with AIFA – Italian Regulatory Agency), Marketing (GI, GU, Gyn indications), Digital and Innovation, Patient Advocacy and External Communications.

Academic Career

- Member of the Young Oncologists Group of the Italian Society of Medical Oncology
- Scientific Committee Member for the American Society of Clinical Oncology Annual Meeting for 3 consecutive years (2017-2019)
- Invited Speaker and Lecturer at National and International Meetings and Congresses (more than 500 talks 2006-2021)
- Oral Presenter at ASCO, ESMO, ESMO GI, AIOM Annual Meetings.
- Active Member of Major Cooperative Groups and International Networks (i.e. GONO Foundation, GISCAD, ARCAD group for digestive cancers)
- Principal or Co-Investigator of Sponsored and No-profit Phase 2 and Phase 3 trials (3 of them led to drug approval registration and sites have been FDA Inspected). Extensive experience in clinical study conception, design, conduction, monitoring, analysis and publication.
- Scientific commitment and research programs led to authoring and co-authoring more than 260 full papers indexed in PubMed. Best 15 publications are listed below (Appendix) and include first-authoring of full research papers in The New England Journal of Medicine, The Lancet Oncology and Journal of Clinical Oncology among those with the highest impact factor.
- Associate and Full Professor in Medical Oncology Licenses – Italian Ministry of University and Research.

Appendix – BEST SCIENTIFIC PUBLICATIONS PEER REVIEWED JOURNALS WITH IMPACT FACTOR

	Title - Authors - Journal	Year
1.	<p>Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.</p> <p>Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S.</p> <p>J Clin Oncol. 2021 Feb 1;39(4):273-284.</p> <p>doi: 10.1200/JCO.20.02088.</p> <p>PMID: 33503393</p>	2021
2.	<p>Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial.</p> <p>Pasqualetti G, Schirripa M, Dochy E, Fassan M, Zirano P, Puzzone M, Scartozzi M, Alberti G, Lonardi S, Zagonel V, Monzani F, Loupakis F.</p> <p>Eur J Cancer. 2020 May 20;133:66-73.</p> <p>PMID: 32446145</p> <p>doi: 10.1016/j.ejca.2020.04.023.</p>	2020
3.	<p>Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.</p> <p>Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators.</p> <p>Lancet Oncol. 2020 Apr;21(4):497-507.</p> <p>PMID: 32164906</p> <p>doi: 10.1016/S1470-2045(19)30862-9.</p>	2020
4.	<p>Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.</p> <p>Loupakis F, Depetris I, Biason P, Intini R, Prete AA, Leone F, Lombardi P, Filippi R, Spallanzani A, Cascinu S, Bonetti LR, Maddalena G, Valeri N, Sottoriva A, Zapata L, Salmaso R, Munari G, Ruge M, Dei Tos AP, Golovato J, Sanborn JZ, Nguyen A, Schirripa M, Zagonel V, Lonardi S, Fassan M.</p> <p>Oncologist. 2020 Jan 22.</p> <p>PMID: 31967692</p> <p>doi: 10.1634/theoncologist.2019-0611.</p>	2020
5.	<p>Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal</p>	2019

Cancer.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, **Loupakis F**, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J.

N Engl J Med. 2019 Sep 30.

PMID: 31566309.

DOI: 10.1056/NEJMoa1908075.

6. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. 2019

Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, **Loupakis F**, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F.

J Clin Oncol. 2019 Sep 20;JCO1901254.

DOI: 10.1200/JCO.19.01254

7. CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. 2019

Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M.

Br J Cancer. 2019 Sep 2.

PMID: 31474758

DOI: 10.1038/s41416-019-0560-0

8. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. 2019

Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, Di Maio M.

Eur J Cancer. 2019 Jul 19;118:121-130.

PMID: 31330487

DOI: 10.1016/j.ejca.2019.06.008.

9. Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization. 2019

Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V,

Loupakis F, Fassan M.

Clin Cancer Res. 2019 Apr 9.

PMID: 30967421

DOI: 10.1158/1078-0432.CCR-19-0311

10. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. 2015

Loupakis F, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, Casagrande M, Ferrari L, Salvatore L, Schirripa M, Rossini D, De Maglio G, Fasola G, Calvetti L, Pilotto S, Carbognin L, Fontanini G, Tortora G, Falcone A, Sperduti I, Bria E.

Br J Cancer. 2015 Nov 17.

PMID: 26575603.

DOI: 10.1038/bjc.2015.399

11. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. 2015

Cremolini C, **Loupakis F**, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.

Lancet Oncol. 2015 Aug 28.

PMID: 26338525.

DOI: 10.1016/S1470-2045(15)00122-9

12. Primary tumor location as a prognostic factor in metastatic colorectal cancer. 2015

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ.

J Natl Cancer Inst. 2015 Feb 24;107(3).

PMID: 25713148

DOI: 10.1093/jnci/dju427

13. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. 2014

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.

N Engl J Med. 2014 Oct 23;371(17):1609-18.

PMID: 25337750

DOI: 10.1056/NEJMoa1403108

14. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. 2009

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.

Br J Cancer. 2009 Aug 18;101(4):715-21. Epub 2009 Jul 14.

PMID: 19603018

DOI: 10.1038/sj.bjc.6605177

15. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

2009

Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A.

J Clin Oncol. 2009 Jun 1;27(16):2622-9.


PMID: 19398573

DOI: 10.1200/JCO.2008.20.2796

Viterbo, May 28th 2026

Personal data use authorized according to the Italian Law D.Lgs 196/03.

Autorizzo il trattamento dei miei dati personali ai sensi del Regolamento UE 2016/679 sul trattamento dei dati personali e del precedente d.lgs.196/03



LPKFTS79A25G702Y